EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

  • Rheumatoid Arthritis
Trial Status:

Completed

This trial runs in
Cities
  • Agios Syllas, Kavala
  • Athens
  • Athina
  • Chaidari
  • Ioannina
  • Karditsa
  • Marousi
  • Mitilini
  • Nea Smyrni
  • Patra
  • Patras
  • Thessaloniki
  • Volos
Trial Identifier:

NCT02648035 ML29855

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.

      Hoffmann-La Roche Sponsor
      NCT02648035 , ML29855 Trial Identifier
      Tocilizumab Treatments
      Rheumatoid Arthritis Condition
      Official Title

      Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
        - Aged >/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to approved label within 4 weeks prior to enrolment.
      Exclusion Criteria
      • Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to enrolment.
      • Participants who have received TCZ in past treatments.
      • Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) of starting treatment TCZ SC.
      • Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now